Abstract
ObjectivesResults from a phase 1b/2 study showed lenvatinib (LEN) + pembrolizumab (pembro) has efficacy in patients (pts) with advanced endometrial carcinoma following prior treatment. Here, we describe the phase 3...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have